Drugs by Condition

Pancreatic Cancer Medications

Definition of Pancreatic Cancer: Pancreatic carcinoma is a malignancy (cancer) of the pancreas.

Drugs (by generic name) associated with Pancreatic Cancer

The following drugs and medications are in some way related to, or used in the treatment of Pancreatic Cancer. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Drug Name ( View by: Brand \| Generic )	Reviews	Ratings
bevacizumab systemic (Pro, More...) class: antineoplastic monoclonal antibodies, tyrosine kinase inhibitors, VEGF/VEGFR inhibitors	1 review(s)	Rate It!	9.0
erlotinib systemic (Pro, More...) class: EGFR inhibitors, tyrosine kinase inhibitors	1 review(s)	Rate It!	5.0
pancreatin systemic (More...) class: digestive enzymes	0 review(s)	Not rated - Be the first
streptozocin systemic (Pro, More...) class: alkylating agents	0 review(s)	Not rated - Be the first
mitomycin systemic (Pro, More...) class: antibiotics/antineoplastics	0 review(s)	Not rated - Be the first
methotrexate systemic (Pro, More...) class: antimetabolites, antipsoriatics, antirheumatics	0 review(s)	Not rated - Be the first
cetuximab systemic (Pro, More...) class: antineoplastic monoclonal antibodies, EGFR inhibitors, tyrosine kinase inhibitors	0 review(s)	Not rated - Be the first
fluorouracil systemic (Pro, More...) class: antimetabolites	0 review(s)	Not rated - Be the first
gemcitabine systemic (Pro, More...) class: antimetabolites	0 review(s)	Not rated - Be the first
capecitabine systemic (Pro, More...) class: antimetabolites	0 review(s)	Not rated - Be the first

Pancreatic Cancer Medications in the Pipeline

Virulizin

June 13, 2005 - U.S. FDA Agrees to Rolling New Drug Application for Virulizin

Orathecin (rubitecan)

January 3, 2005 - SuperGen Announces Withdrawal of Orathecin NDA
November 29, 2004 - SuperGen Announces 90 Day Extension of FDA Review Date for Orathecin New Drug Application
March 26, 2004 - SuperGen’s New Drug Application for Orathecin (rubitecan) capsules accepted by FDA for filing
March 26, 2004 - SuperGen’s New Drug Application for Orathecin (rubitecan) capsules accepted by FDA for filing
January 28, 2004 - SuperGen completes submission of New Drug Application (NDA) for Orathecin as an oral treatment for pancreatic cancer

Latest Pancreatic Cancer Blog Post

Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
New Data from a Phase 3 Trial Presented NEW YORK--(BUSINESS WIRE)--Jun 25, 2009 - Pfizer today announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic...

View all Pancreatic Cancer blog posts.

Pancreatic Cancer Support Group Questions

Go to the Pancreatic Cancer support group or view all Pancreatic Cancer questions.

Ask a Question about Pancreatic Cancer:

Browse drugs by condition:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z